Show simple item record

dc.contributor.authorAndratschke, Nicolaus
dc.contributor.authorWillmann, Jonas
dc.contributor.authorAppelt, Ane L
dc.contributor.authorAlyamani, Najlaa
dc.contributor.authorBalermpas, Panagiotis
dc.contributor.authorBaumert, Brigitta G
dc.contributor.authorHurkmans, Coen
dc.contributor.authorHøyer, Morten
dc.contributor.authorLangendijk, Johannes A.
dc.contributor.authorKaidar-Person, Orit
dc.contributor.authorvan der Linden, Yvette
dc.contributor.authorMeattini, Icro
dc.contributor.authorNiyazi, Maximilian
dc.contributor.authorReynaert, Nick
dc.contributor.authorDe Ruysscher, Dirk
dc.contributor.authorTanadini-Lang, Stephanie
dc.contributor.authorHoskin, Peter
dc.contributor.authorPoortmans, Philip
dc.contributor.authorNieder, Carsten
dc.date.accessioned2023-03-13T12:52:17Z
dc.date.available2023-03-13T12:52:17Z
dc.date.issued2022-09-26
dc.description.abstractRe-irradiation can be considered for local recurrence or new tumours adjacent to a previously irradiated site to achieve durable local control for patients with cancer who have otherwise few therapeutic options. With the use of new radiotherapy techniques, which allow for conformal treatment plans, image guidance, and short fractionation schemes, the use of re-irradiation for different sites is increasing in clinical settings. Yet, prospective evidence on re-irradiation is scarce and our understanding of the underlying radiobiology is poor. Our consensus on re-irradiation aims to assist in re-irradiation decision making, and to standardise the classification of different forms of re-irradiation and reporting. The consensus has been endorsed by the European Society for Radiotherapy and Oncology and the European Organisation for Research and Treatment of Cancer. The use of this classification in daily clinical practice and research will facilitate accurate understanding of the clinical implications of re-irradiation and allow for cross-study comparisons. Data gathered in a uniform manner could be used in the future to make recommendations for re-irradiation on the basis of clinical evidence. The consensus document is based on an adapted Delphi process and a systematic review of the literature was done according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).en_US
dc.identifier.citationAndratschke, Willmann, Appelt, Alyamani, Balermpas, Baumert, Hurkmans, Høyer, Langendijk, Kaidar-Person, van der Linden, Meattini, Niyazi, Reynaert, De Ruysscher, Tanadini-Lang, Hoskin, Poortmans, Nieder. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. The Lancet Oncology. 2022;23(10):e469-e478en_US
dc.identifier.cristinIDFRIDAID 2061725
dc.identifier.doi10.1016/S1470-2045(22)00447-8
dc.identifier.issn1470-2045
dc.identifier.issn1474-5488
dc.identifier.urihttps://hdl.handle.net/10037/28729
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalThe Lancet Oncology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleEuropean Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision makingen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)